Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 16, 2024 -- For individuals with heart failure with reduced ejection fraction (HFrEF), substantial mortality benefits would result from optimal use of guideline-directed medical therapy (GDMT), according to a study published online Oct. 2 in JAMA Cardiology.
Amber B. Tang, M.D., from the University of California Los Angeles, and colleagues examined the projected population-level benefit of optimal GDMT use globally among patients with HFrEF based on data derived from previously published studies.
Overall, 8,235,063 of an estimated 28.89 million people worldwide with HFrEF were potentially eligible for but not receiving β-blockers; 20,387,000 were eligible for but not receiving angiotensin receptor-neprilysin inhibitors; 12,223,700 were eligible for but not receiving mineralocorticoid receptor antagonists; and 21,229,170 were eligible for but not receiving sodium glucose cotransporter-2 inhibitors. The researchers found that 1,188,277 deaths could potentially be prevented over 12 months with optimal implementation of quadruple GDMT. Many of these deaths were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions.
"Although future studies are needed to better understand the heterogeneity that exists within each region and potential interventions targeted to different settings, these findings demonstrate the urgent need for improved implementation of GDMT therapies worldwide," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Wildfire Smoke Exposure Increases Risk for Heart Failure
TUESDAY, July 8, 2025 -- Wildfire smoke exposure over time may increase the risk for heart failure, according to a study published in the July issue of the Journal of the...
A-Fib Catheter Ablation Cuts Risk for Ischemic Stroke After 30 Days, Mortality, Heart Failure Hospitalization
MONDAY, July 7, 2025 -- For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, mortality, and heart failure...
Urinary Metal Levels Tied to Increased Risk for Later Heart Failure
THURSDAY, July 3, 2025 -- There are consistent associations between elevated urinary metal levels and increased heart failure risk over time across geographically diverse cohorts...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.